AMBS News Alert Amarantus Biosci Inc (AMBS) 0.0900 10/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amarantus Biosci Inc (AMBS) 0.0900 $AMBS

Amarantus Requests Pre-IND Feedback From FDA for Eltoprazine Phase IIb Parkinson's Disease Levodopa-Induced Dyskinesia Clinical Trial
GlobeNewswire - Mon Sep 29, 1:03PM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutics for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced it has submitted a request to the FDA for a review and written feedback of the Phase IIb clinical trial design for Eltoprazine in levodopa-induced dyskinesia (LID), a common side effect of levodopa treatment in Parkinson's disease (PD) patients.

Amarantus Shareholders Approve All Matters Voted Upon at Annual Shareholders Meeting
GlobeNewswire - Thu Sep 25, 3:00PM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutics for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, is pleased to announce the approval of all matters put forth to a vote of the shareholders at the company's Annual Shareholders Meeting.

Amarantus BioScience Holdings, Inc. - "Fundamental Milestones Ahead: Up-Listing from Strength"
ACCESSWIRE - Thu Sep 18, 12:05PM CDT
New York, NY / ACCESSWIRE / September 18, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Market Maker Surveillance Report. TIVO, MDT, CTSH, RHHBY, NVLX, AMBS, Highest Net Sell Volume and Negative Price Friction For Wednesday, September 17th 2014
M2 - Thu Sep 18, 3:30AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Wednesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. TIVO INCORPORATED (NASDAQ:TIVO), Medtronic Inc (NYSE:MDT), Cognizant Technology Solutions Corp (NASDAQ:CTSH), Roche Holding AG (OTC:RHHBY), Nuvilex Inc (OTC:NVLX), Amarantus BioSciences Inc (OTC:AMBS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Amarantus Provides Program Update on Phase 2b Eltoprazine for Parkinson's Disease and Adult ADHD
GlobeNewswire - Wed Sep 17, 8:28AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutics for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today provided a program update on its Phase 2b-ready Eltoprazine program for Parkinson's disease levodopa-induced dyskinesia patients ("PD LID" and adult attention deficit and hyperactivity disorder ("Adult ADHD" . The company expects to initiate its Phase 2b PD LID clinical trial in the fourth quarter of 2014 or early in 2015.

Amarantus Completes Enrollment of 72 Patient LP-002 Clinical Study for Alzheimer's Blood Diagnostic LymPro Test(R)
GlobeNewswire - Fri Sep 12, 9:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced that it has completed enrollment of the originally planned 72 patient LP-002 clinical study to assess the commercial feasibility of the company's flagship Alzheimer's blood diagnostic LymPro Test(R). Amarantus previously released positive interim data from LP-002 on July 31, 2014 and expects to release data on the predictive value of individual LymPro markers (univariate) from the full cohort of 72 patients in the coming weeks.

Amarantus to Present Orphan Ocular Data at Targeting Ocular Disorders Conference 2014
GlobeNewswire - Wed Sep 10, 12:00PM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced that Dr. Roman Urfer, Chief Development Officer at NeuroAssets Sarl, will be presenting efficacy data for MANF in an undisclosed orphan ocular indication at Targeting Ocular Disorders 2014. NeuroAssets is a Swiss-based neuroscience-focused consulting firm engaged by Amarantus to support the translational development of MANF. Dr. Urfer's presentation will be made at 3:40pm ET on October 6, 2014 at the Westin Boston Waterfront Market in Boston, MA.

Amarantus Announces Positive MANF Ocular Toxicology Data
GlobeNewswire - Tue Sep 09, 7:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced positive 15-day non-GLP toxicology data for a single intravitreal administration of MANF in an ocular safety animal model, relevant to MANF's development in ocular diseases, including orphan indications such as Retinitis Pigmentosa. The intravitreal method of administration was chosen because it is the delivery method expected for human application of MANF. The experiments were conducted at a leading ophthalmology contract research laboratory in France.

Market Maker Surveillance Report. AMAT, BAC, SIRI, AAPL, CNC, AMBS, Highest Net Sell Volume and Negative Price Friction For Wednesday, September 3rd 2014
M2 - Thu Sep 04, 10:09AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4918 companies with "abnormal" market making, 2306 companies with positive Friction Factors and 2830 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Wednesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. APPLIED MATERIALS, INC. (NASDAQ:AMAT), BANK OF AMERICA CORPORATION (NYSE:BAC), Sirius XM Radio Inc (NASDAQ:SIRI), Apple Inc (NASDAQ:AAPL), CENTENE CORPORATION (NYSE:CNC), Amarantus BioSciences Inc (OTC:AMBS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Amarantus to Present at Sachs Associates 14th Annual Biotech in Europe Forum for Global Partnering and Investment
GlobeNewswire - Thu Sep 04, 9:34AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, announced that Gerald E. Commissiong, President and CEO, is scheduled to present at the 14 Annual Biotech in Europe Forum at the Congress Center in Basel, Switzerland. The presentation is scheduled for Wednesday, October 1 at 11:45 AM in the Darwin Room. Mr. Commissiong's presentation will be web cast live and available on the company's web site at www.amarantus.com.

Amarantus BioScience Holdings, Inc. - "Initiating Studies for CLIA Launch at Icon Central Laboratories"
ACCESSWIRE - Tue Sep 02, 7:26AM CDT
New York, NY / September 2, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's President and CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Amarantus Initiates CLIA Development of Alzheimer's Blood Diagnostic LymPro Test(R) at ICON Central Laboratories
GlobeNewswire - Tue Sep 02, 5:14AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, announced it has entered into a Master Services Agreement with ICON for global therapeutic and diagnostic clinical development services. Amarantus has submitted an initial work order to ICON for delivery of the Fit for Purpose Flow Cytometry Assay Validation of the company's flagship Alzheimer's blood diagnostic LymPro Test(R) at ICON's CLIA-certified Central Laboratory facility in Farmingdale, NY.

Amarantus elects Iain Ross to board
M2 - Mon Sep 01, 3:29AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) revealed on Friday the addition of Iain Ross to its board of directors.

Amarantus Appoints Iain Ross to Board of Directors
GlobeNewswire - Fri Aug 29, 6:56AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced the appointment of Mr. Iain Ross to the Company's Board of Directors, Mr. Ross brings over 30 years of biopharmaceutical industry experience to Amarantus across executive management, investment and directorship roles.

Amarantus Reports Second Quarter 2014 Financial Results, Announces Business Update Call
GlobeNewswire - Wed Aug 27, 8:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, reported financial results for the second quarter ended June 30, 2014 and announced a business update call on September 2, 2014. At August 27, 2014, the Company had cash and cash equivalents totaling approximately $2.4 million.

Amarantus to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Aug 19, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO, is scheduled to present to investors at the 16th Annual Rodman & Renshaw Healthcare Conference to be held September 8-10, 2014 at the New York Palace Hotel in New York City. The presentation is scheduled for Tuesday, September 9th at 2:30 PM ET and will be web cast live, please visit the Company's IR Events section to participate. Additional information about the conference can be found at http://www.rodm.com/.

Amarantus announces exercise of option to license intellectual property from University of Miami Bascom Palmer Eye Institute for retinal disorders
M2 - Mon Aug 18, 6:39AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) reported on Friday that it has exercised its exclusive perpetual option to license intellectual property related to MANF's utility in treating retinal disorders from the University of Miami's Bascom Palmer Eye Institute.

Amarantus Exercises Option to License Intellectual Property From University of Miami Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders
GlobeNewswire - Fri Aug 15, 7:10AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced that it exercised its exclusive option to license intellectual property related to MANF's utility in treating retinal disorders from the University of Miami's Bascom Palmer Eye Institute, and has entered into an exclusive license for said intellectual property. Under the terms of the agreement, the Company has been granted a perpetual, exclusive worldwide license to intellectual property, covering the use of MANF for the treatment of retinal disorders, including Retinitis pigmentosa.

Amarantus BioScience Holdings, Inc. "Preparing Amarantus for the Up-list in 2H-14: Capital Markets Strategy"
ACCESSWIRE - Mon Aug 11, 7:03AM CDT
New York, NY / ACCESSWIRE / August 11, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, co-written by the Company's CEO, Mr. Gerald Commissiong and Chief Financial Officer, Mr. Robert Farrell, JD. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Amarantus Enters Into Research Collaboration With the Buck Institute for Research on Aging for MANF
GlobeNewswire - Mon Aug 11, 7:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced it has entered into a Research Collaboration with theBuck Institute for Research on Aging for the development of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) in undisclosed therapeutic indications. MANF is a targeted therapeutic which addresses the underlying programmed cell death (apoptosis) associated with a wide range of devastating human disorders including orphan indications such as Retinitis Pigmentosa.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Scientific Games Takes Big Buck Hunter to Lotteries

Updated Category News Views 84

A mounted arcade cabinet is an odd place to find lottery growth, yet Scientific Games may be onto something with its exclusive Big Buck Hunter licensing deal. Announced November 19, 2026, the arrangement lets the company carry a 26-year-old arcade franchise into U.S. and Canadian instant scratch games, Fast Play, draw games, digital products and second-chance promotions....

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 57

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading
Live Nation Tests Creator Content With Morgan Jay Series

Updated Category News Views 157

A comedian turning crowd work into songs is hardly a boardroom event, but this one has a useful wrinkle: Live Nation Studios put financing behind it. Morgan Jay and Austin-based agency Hello Party launched Music Therapy with Morgan Jay on YouTube on November 18, with Kam Patterson opening the season. The show pairs Jay and celebrity guests for loose conversation,...

Continue Reading
Eight O'Clock Adds Blonde Roast Pods to Its Lineup

Updated Category News Views 166

A lighter cup of coffee just became Eight O'Clock Coffee's newest swing at the single-serve shelf. On Nov. 19, 2026, the company said it introduced Blonde Roast K-Cup pods, a bright and smooth option aimed at drinkers who prefer a lighter roast. The product is available through Keurig.com and Amazon. That is the whole announcement, and frankly it is better to keep it that...

Continue Reading
CMA Wins Spotlight Greenberg Traurig’s Music Bench

Updated Category News Views 119

Four trophies on one awards night can say plenty about the machinery behind a music career, even if nobody should confuse a CMA acceptance speech with a balance-sheet event. Greenberg Traurig’s entertainment practice is celebrating client wins at the 60th annual CMA Awards, held Nov. 18, 2026: three honors tied to Miranda Lambert and one for Brooks & Dunn. For investors...

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 56

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
BreakBio's New CSO Adds Vaccine Trial Credibility in Cancer

Updated Category News Views 144

Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...

Continue Reading
Clickstop's Urbana Expansion Bets on Durable Demand

Updated Category News Views 81

A patch of turned Iowa dirt can say plenty about a company’s nerve. Clickstop broke ground in Urbana on Nov. 19, 2026, for a 43,000-square-foot building, and the message is pretty plain: management believes its recent growth has legs. For a privately held, employee-owned operator serving trucking, construction, lifting and rigging, that is not a casual decision....

Continue Reading
Zensar’s AI Forum Puts Operations Before the AI Hype

Updated Category News Views 47

Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...

Continue Reading
HLRBO's Data-Heavy Rebuild Changes Hunting Lease Market

Updated Category News Views 149

A hunting lease used to begin with hearsay, blurry photos, and a whole lot of hoping. HLRBO is trying to drag that stubbornly analog process into a data-rich, phone-first marketplace, and frankly, it is about time. The company rebuilt its web and mobile platforms around parcel information, plain-language AI search, mobile lease completion, and its Land IQ™ scoring...

Continue Reading

Top 5 Most Recently Viewed Articles

Jeff Ettinger Returns to Hormel Foods Board Leadership Today

Updated Category News Views 219

Jeff Ettinger Returns to Hormel Foods Board Leadership Today Hormel Foods Corporation (NYSE: HRL), a leading global branded food company, recently announced the reappointment of Jeff Ettinger to its Board of Directors. With extensive experience in the food industry, including nearly three decades at Hormel, Ettinger's appointment marks an important step for the company....

Continue Reading
NEXGEL Welcomes Finance Expert Steve Ciardiello to Board

Updated Category News Views 238

NEXGEL Welcomes New Board Member for Growth and Innovation NEXGEL, Inc. (NASDAQ: NXGL), a prominent provider of medical and over-the-counter (OTC) products, has announced a significant addition to its Board of Directors. The company has appointed Steve Ciardiello, CPA, currently the Chief Accounting Officer of Shutterstock, Inc. (NYSE: SSTK), to its board. This decision...

Continue Reading
Exploring Bitcoin's Potential to Reach $200,000 by 2025

Updated Category News Views 250

Bernstein’s 2025 Bitcoin Target In an insightful report, analysts from Bernstein set forth ambitious predictions for Bitcoin, speculating that the price could soar to $200,000 by the end of 2025. This forecast stems from increasing institutional interest and Bitcoin's inherently limited supply, factors which highlight its potential as a premier store of value. “As...

Continue Reading
Innovent Launches First Patient Dosing for New DME Treatment

Updated Category News Views 256

Innovent's Groundbreaking Clinical Study Begins Innovent Biologics, Inc. (HKEX: 01801) has marked a significant milestone in ophthalmic therapy with the initiation of first patient dosing in a Phase 2 clinical study focusing on efdamrofusp alfa (IBI302). This innovative treatment represents a first-in-class bispecific fusion protein specifically designed to address...

Continue Reading
Arrow Tool Group Taps Hong to Drive Growth Strategy

Updated Category News Views 42

Big Moves at Arrow Tool Group There's a new sheriff in town at Arrow Tool Group, folks. Say hello to Chee Min Hong, the newly minted Vice President of Product Management, eCommerce & Brand Marketing. From what I gather, this isn't Hong's first rodeo. Having spent over 25 years wrangling product portfolios and fine-tuning brand strategies for giants like MANSCAPED and...

Continue Reading